

Supplimentray Table 1:

ID	Tumor Type	Agent/Regimen	Dose (mg/Kg)/Route/Schedule	MOA	TGI	% Responses
JH033	PDAC	AZ0530	50; PO; QDX28	Src kinase inhibitor	0	0
		BI6727	50; IV; Q7DX4	PLK1 inhibitor	68	0
		CS1008	3; IV; Q7DX4	DR5 agonist	11	0
		Cisplatin	2; IP; QDX5	DNA damage	100	10
		Docetaxel	20; IV; Q7DX4	Microtubule damage	100	0
		E7080	100; PO; QDX28	Multi kinase inhibitor	86	0
		Gemcitabine	100; IP; Q3DX4	DNA replication	50	0
		MK1757	30;PO; Q7DX4	Wee inhibitor	30	0
		Mibefradil	65; PO; BID;QDX28	T Ca channel inhibitor	32	0
		ON1419.Na	250; IP; QDX28	PLK1 inhibitor	30	0
		Erlotinib	50; IP; QDX28	EGFR inhibitor	79	0
		Radiation Therapy	5 cGy; Q2DX1	DNA damage	96	0
		Rapamycin	100; PO; QDX10	mTOR inhibitor	50	0
		Rottlerin	0.5;IP;QDX28	PKCδ inhibitor	37	0
		Mitomycin	5;IV; QDX1	DNA damage	100	0
		PHA-848125	40;PO; BID;QDX28	Cdk inhibitor	41	0
		Gemcitabine + AZD0530	100; IP; Q3DX4 50; PO; QDX28	DNA replication Src kinase inhibitor	50	0
		Gemcitabine + CS1008	100; IP; q3dx4 3; IV; Q7DX4	DNA replication DR5 agonist	60	0
		Gemcitabine + Erlotinib	100; IP; Q3DX4 50; IP; QDX28	DNA replication EGFR inhibitor	56	0
		Gemcitabine + Rapamycin	100; IP; Q3DX4 100; PO; QDX10	DNA replication mTOR inhibitor	67	0
Gemcitabine + Rottlerin	100; IP; Q3DX4 0.5;IP;QDX28	DNA replication PKCδ inhibitor	43	0		
Mitomycin + Rapamycin	5;IV; QDX1 100; PO; QDX10	DNA damage mTOR inhibitor	31	0		
ON1419.Na + Rapamycin	250; IP; QDX28 100; PO; QDX10	PLK inhibitor mTOR inhibitor	43	0		
CBI-0805	CRC	Irinotecan + Bevacizumab	50; IP; Q7DX3 10; IP; Q3DX6	Topoisomerase 1 inhibitor VEGF inhibitor	100	56
		Irinotecan + Cetuximab	50; IP; Q7DX3 4; IP; Q7DX8	Topoisomerase 1 inhibitor EGFR inhibitor	100	0
		Irinotecan + Capecitabine	50; IP; Q7DX3 500; PO; QDX18	Topoisomerase 1 inhibitor Thymidylate synthase Inhibitor	100	1
		Oxaliplatin + Capecitabine	4; IV; Q4DX3 500; PO;QDX18	DNA damage Thymidylate synthase inhibitor	74	0
		Irinotecan + Sorafenib	50; IP; Q7DX3 40; PO; QDX18	Topoisomerase 1 inhibitor Multi kinase inhibitor	100	60
		Sorafenib + Bevacizumab	40; PO; QDX18 10; IP; Q3DX6	Multi kinase inhibitor VEGF inhibitor	74	0
		Irinotecan	100; IP; Q7DX3	Topoisomerase I inhibitor	100	100
		Irinotecan + Temsirolimus	25; IP; Q7DX3 10; IV; Q3DX5	Topoisomerase I inhibitor mTOR inhibitor	113	50
		Irinotecan +	25; IP; Q7DX3	Topoisomerase I inhibitor	117	20

		Lapatinib	50; PO; QDX21	HER2 inhibitor	...	20
		Everolimus + Lapatinib	100; PO; QDX21 50; PO; QDX21	mTOR inhibitor HER2 inhibitor	86	10
		Sorafenib + Capecitabine	40; PO; QDX21 500; PO; QDX21	Multi kinase inhibitor Thymidylate synthase Inhibitor	93	0
		Pemetrexed	100; IP; QDX5X2	Antifolate	63	0
		Pemetrexed + Lapatinib	100; IP; QDX5X2 50; PO; QDX19	Antifolate HER2 inhibitor	61	0
CBI0803	Gastroesophageal	Nab-paclitaxel	60; IV; Q4DX3	Microtubule damage	111	0
		Ixabepilone	10; IP; Q4DX3	Microtubule damage	113	90
		Nab-paclitaxel Sunitinib	60; IV; Q4DX3 40; PO; QDX28	Microtubule damage Multi kinase inhibitor	115	80
		Nab-paclitaxel Sorafenib	60; IV; Q4DX3 60; PO; QDX28	Microtubule damage Multi kinase inhibitor	114	80
		Nab-paclitaxel Temsirolimus	60; IV; Q4DX3 10; IV; Q3DX5	Microtubule damage mTOR inhibitor	110	0
		Nab-paclitaxel Bortezomib	60; IV; Q4DX3 0.5; IV; Q3DX4	Microtubule damage Proteasome inhibition	111	0
		Gemcitabine + Sunitinib	80; IP; Q3DX4 40; QDX28	DNA replication Multi kinase inhibitor	109	0
		Gemcitabine + Sorafenib	80; IP; Q3DX4 60; PO; QDX28	DNA replication Multi kinase inhibitor	110	0
		Gemcitabine + Temsirolimus	80; IP; Q3D 10; IV; Q3DX5	DNA replication mTOR inhibitor	107	0
		Gemcitabine + Bortezomib	80; IP; Q3DX4 0.5; IV; Q3DX4	DNA replication Proteasome inhibitor	94	0
		Mitomycin C + Sunitinib	1; IP; Q7DX3 40; PO; QDX28	DNA damage Multi kinase inhibitor	107	0
		Mitomycin C + Bevacizumab + Sorafenib	1; IP; Q7DX3 5; IP Q3DX6 60; PO; QDX18	DNA damage VEGF inhibitor Multi kinase inhibitor	106	0
		Mitomycin C + Temsirolimus	1; IP; Q7DX3 10; IV; Q3DX5	DNA damage mTOR inhibitor	107	0
		Mitomycin-C + Bortezomib	1; IP; Q7DX3 0.5; IV; Q3DX4	DNA damage Proteasome inhibitor	72	0
		Epirubicin	10; IV; Q7DX3	Topoisomerase II inhibitor	88	0
		Mitomycin-C	5; IP; Q7DX3	DNA damage	111	0
		Bevacizumab	5; IP; Q3DX6	VEGF inhibitor	86	0
		Gemcitabine	80; IP; Q3DX4	DNA replication	69	0
		Irinotecan	100; IP; Q7DX3	Topoisomerase 1 inhibitor	103	56
		Cetuximab	10; IP; Q3DX6	EGFR inhibitor	--	0
		Sunitinib	40; PO; QDX18	Multi kinase inhibitor	87	0
		Sorafenib	60; PO; QDX18	Multi kinase inhibitor	102	0
		Erlotinib	50; PO; QDX18	EGFR inhibitor	2	0
		Lapatinib	100; PO; QDX18	HER2 inhibitor	49	0
		Nab-paclitaxel Bevacizumab	100; IV; Q4DX3 5; IP; Q3DX6	Microtubule damage VEGF inhibition	106	0
		Mitomycin-C + Bevacizumab	5; IV; Q7DX3 5; IP; Q3DX6	DNA damage VEGF inhibition	111	0

		Gemcitabine + Bevacizumab	80; IP; Q4DX3 5; IP; Q3DX6	DNA damage VEGF inhibition	101	0
		Sunitinib + Bevacizumab	40; PO; QDX18 5; IP; Q3DX6	Multi kinase inhibitor VEGF Inhibition	89	0
		Sorafenib + Bevacizumab	60; PO; QDX18 5; IP; Q3DX6	Multi kinase inhibitor VEGF Inhibition	102	0
		Erlotinib + Bevacizumab	50; PO; QDX18 5; IP; Q3DX6	EGFR Inhibitor VEGF Inhibition	79	0
		Lapatinib + Bevacizumab	100; PO; QDX18 5; IP; Q3DX6	HER2 inhibitor VEGF inhibition	84	0
		5-FU + Oxaliplatin	15; IP; QDX5 4; IV; Q4DX3	TS inhibitor DNA damage	64	0
		Irinotecan + Cetuximab + Bevacizumab	100; IP; Q7DX3 10; IP; Q3DX6 5; IP; Q3DX6	Topoisomerase 1 inhibitor EGFR inhibitor VEGF Inhibitor	109	0
		Ixabepilone	5/4/4; IV; Q7DX3	Microtubule damage	103	78
		Vandetanib	50; PO; QDX18	VEGFR inhibitor	87	0
		Vinflunine	30; IP; Q7DX4	Microtubule damage	63	0
		Arsenic Trioxide	3; IV; QODX10	Apoptosis induction	0	0
		Vandetanib + Ixabepilone	50; PO; QDX18 5/4/4; IV; Q7DX3	VEGFR inhibitor Microtubule damage	105	75
		Vinflunine + Ixabepilone	50; PO; QDX18 5/4/4; IV; Q7DX3	Microtubule damage Microtubule damage	100	100
		Arsenic Trioxide + Ixabepilone	3; IV; QODX14 5/4/4; IV; Q7DX3	Apoptosis induction Microtubule damage	104	75
CBI-0601	Leiomyosarcoma	Irinotecan + Bevacizumab	100; IP; Q7DX3 10; IP; Q3DX10	Topoisomerase 1 Inhibitor VEGF Inhibitor	34	0
		Bortezomib + Bevacizumab	1; IV; Q3DX6 10; IP; Q3DX10	Proteasome inhibitor VEGF inhibitor	83	0
		Rapamycin + Bevacizumab	8; PO; QDX14 10; IP; Q3DX10	mTOR inhibitor VEGF Inhibitor	92	0
		Gemcitabine + Docetaxel + Bevacizumab	40; IP; Q3DX4 6.3; IV; Q2DX3 10; IP; Q3DX10	DNA replication Microtubule damage VEGF inhibitor	100	27
		Doxorubicin + Bevacizumab	2; IV; QDX5 10; IP; Q3DX10	DNA damage VEGF inhibitor	59	17
		Perifosine + Bevacizumab	30; PO; QDX28 10; IP; Q3DFX10	Akt inhibitor VEGF inhibitor	71	0
		Sorafenib	60; PO; QDX10	Multi kinase inhibitor	0	0
		Sorafenib + Bevacizumab	60; PO; QDX10 10; IP; Q3DX10	Multi kinase inhibitor VEGF inhibitor	63	0
		Temozolomide	70; IP; QDX5	DNA damage	43	0
		Temozolomide + Sorafenib	70; IP; QDX5 10; IP; Q3DX10	DNA damage Multi kinase inhibitor	81	0
		Bevacizumab	10; IP; Q3DX10	VEGF inhibitor	26	33
		SAHA	50; IP; QDX21	Histone deacetylase inhibitor	0	0
		SAHA + Bevacizumab	50; IP; QDX21 10; IP; Q3DX10	Histone deacetylase inhibitor VEGF inhibitor	27	0
		Thalidomide	200; IP; QDX21	Antiangiogenesis	9	0

Thalidomide + Bevacizumab	200; IP; QDX21 10; IP; Q3DFX10	Antiangiogenesis VEGF inhibitor	41	0
Nab-paclitaxel + Bevacizumab	50; IV; Q4DX3 10; IP; Q3DX10	Microtubule damage VEGF inhibitor	100	100
Nab-paclitaxel + Bevacizumab	50; IV; Q4DX3 10; IP; Q3DX10	Microtubule damage VEGF inhibitor	89	83
Nab-paclitaxel + Bevacizumab + Sorafenib	50; IV; Q4DX3 10; IP; Q3DX10 100; PO; QDX21	Microtubule damage VEGF inhibitor Multi kinase inhibitor	88	80
Nab-paclitaxel + Cisplatin	50; IV; Q4DX3 2; IP; QDX5	Microtubule damage DNA damage	20	0
Nab-paclitaxel + Carboplatin	50; IV; Q4DX3 50; IP; QDX1	Microtubule damage DNA damage	57	0
Docetaxel	10; IV; Q2DX3	Microtubule damage	70	25
Docetaxel + Targretin	10; IV; Q2DX3 100; PO; QDX21	Microtubule damage Retinoid X receptor agonist	79	0
Doxorubicin	2; IP; Q7DX3	Topoisomerase II inhibitor	0	0
Doxorubicin + Ifosfamide	2; IP; Q7DX3 60; IP; QDX3	Topoisomerase II inhibitor DNA damage	0	0
Gemcitabine + Docetaxel + Bevacizumab	40; IP; Q4DX3 6.5; IV; Q2DX3 10; IP; Q3DX10	DNA replication Microtubule damage VEGF inhibitor	87	20
Gemcitabine + Docetaxel + Bevacizumab + Irinotecan	40; IP; Q4DX3 6.5; IV; Q2DX3 10; IP; Q3DX10 50; IP; Q7DX3	DNA replication Microtubule damage VEGF inhibitor Topoisomerase I inhibitor	75	20
Gemcitabine + Docetaxel + Bevacizumab + Temozolomide	40; IP; Q4DX3 6.5; IV; Q2DX3 10; IP; Q3DX10 70; IP; QDX5	DNA replication Microtubule damage VEGF inhibitor DNA damage	98	0
TTP607	30; IP; QD14	Aurora kinase Inhibitor	30	0
TTP607 + Bevacizumab	30; IP; QD14 10; IP; Q3DX10	Aurora kinase inhibitor VEGF inhibitor	59	0
TTP607 + Bevacizumab	30; IP; QD14 10; IP; Q3DX10	Aurora kinase inhibitor VEGF inhibitor	91	0
NB1011	59.75; SC; 14-dayCl	Thymidylate synthase Inhibitor	14	25
NB1011 + Bevacizumab	59.75; SC; 14-dayCl 10; IP; Q3DX10	Thymidylate synthase inhibitor VEGF Inhibitor	31	0
Sorafenib + Docetaxel + Bevacizumab	60; PO; QDX10 6.5; IV; Q2DX3 10; IP; Q3DX10	Multi kinase inhibitor Microtubule damage VEGF inhibitor	69	0
Sorafenib + Docetaxel + Bevacizumab	60; PO; QDX10 6.3; IV; Q2DX3 10; IP; Q3DX10	Multi kinase inhibitor Microtubule damage VEGF inhibitor	76	25
Sunitinib	40; PO; QDX21	Multi kinase inhibitor	39	0
Sunitinib + Docetaxel	40; PO; QDX21 6.3; IV; Q2DX3	Multi kinase inhibitor Microtubule damage	40	0
Sunitinib +	40; PO; QDX21	Multi kinase inhibitor	24	25

		Bevacizumab	10; IP; Q3DX10	VEGF Inhibitor	81	0
		Sunitinib + Docetaxel + Bevacizumab	40; PO; QDX21 6.3; IV; Q2DX3 10; IP; Q3DX10	Multi kinase inhibitor Microtubule damage VEGF inhibitor	63	17
		Sunitinib + Docetaxel + Bevacizumab	40; PO; QDX21 6.5; IV; Q2DX3 10; IP; Q3DX10	Multi kinase inhibitor Microtubule damage VEGF inhibitor	0	0
		Fludarabine	45; IV; Q2DX5	DNA synthesis inhibitor	54	0
		Fludarabine + Bevacizumab	45; IV; Q2DX5 10; IP; Q3DX10	DNA synthesis inhibitor VEGF inhibitor	21	0
		Talabostat	0.8; PO; BIDX28	Dipeptidyl peptidase inhibitor	30	0
		SLX-2119	100; PO; QDX21	ROCK2 inhibitor	37	0
		SLX-3060	100; PO; QDX21	ROCK2 inhibitor		
CBI-0603	NSCLC	Cisplatin	2; IP; QDX5	DNA Damage	70	0
		Sorafenib	40; PO; QDX21	Multi kinase inhibitor	43	0
		Bevacizumab	10; IP; Q3DX10	VEGF Inhibitor	87	0
		Cisplatin + Ranpirnase	2; IV; QDX5 2.5; IV; Q3DX6	DNA damage Ribonuclease inhibitor	46	0
		Sorafenib + Ranpirnase	40; PO; QDX21 2.5; IV; Q3DX6	Multi kinase inhibitor Ribonuclease inhibitor	53	0
		Bevacizumab + Ranpirnase	10; IP; Q3DX10 2.5; IV; Q3DX6	VEGF inhibitor Ribonuclease inhibitor	87	0
		Sorafenib + Bevacizumab	80; PO; QDX21 10; IP; Q3DX10	Multi kinase inhibitor VEGF Inhibitor	92	0
		Sorafenib + Bevacizumab	80; PO; QD 10; IP; Q3D	Multi kinase inhibitor VEGF Inhibitor	98	75
		Sorafenib + Bevacizumab	160; PO; QD 10; IP; Q3D	Multi kinase inhibitor VEGF Inhibitor	99	50
		Ranpirnase	2.5; IV; Q3DX6	Ribonuclease inhibitor	14	0
		Ranpirnase + Sorafenib	2.5; IV; Q3DX6 80; PO; QD	Ribonuclease inhibitor Multi kinase inhibitor	95	25
		Ranpirnase + Cisplatin	2.5; IV; Q3DX6 3; IP; QDX5	Ribonuclease inhibitor DNA damage	62	25
		Ranpirnase + Docetaxel	2.5; IV; Q3D6 13; IV; Q2DX3	DNA damage Microtubule damage	0	0
		Ranpirnase + Irinotecan	2.5; IV; Q3DX6 100; IP; Q7DX3	Ribonuclease inhibitor Topoisomerase 1 inhibitor	47	0
		Ranpirnase + Cetuximab	2.5; IV; Q3DX6 10; IV; Q3D	DNA damage EGFR inhibitor	84	25
		Ranpirnase + Sunitinib +	2.5; IV; Q3DX6 40; PO; QD	DNA damage Multi kinase inhibitor	98	0
		Ranpirnase + Erlotinib	2.5; IV; Q3DX6 100; PO; QD	DNA damage EGFR inhibitor	25	0
		Sorafenib + Bevacizumab	60; PO; QDX10 10; IP; Q3DX10	Multi kinase inhibitor VEGF inhibitor	91	0
		Sorafenib + Bevacizumab + Irinotecan	60; PO; QDX10 10; IP; Q3DX10 10; IP; Q7DX3	Multi kinase inhibitor VEGF inhibitor Topoisomerase I inhibitor	93	0
		Sunitinib +	40; PO; QDX21	Multi kinase inhibitor		

		Bevacizumab	10; IP; Q3DX10	VEGF inhibitor	70	20
		Oxaliplatin + Pemetrexed	2.5; IP; QDX5 75; IP;DX5	DNA damage Antifolate	50	0
		Rapamycin + Erlotinib	8; PO; QDX14 50; PO; QDX14	mTOR inhibitor EGFR inhibitor	20	0
CBI-0701	Myoepithelioma	Docetaxel	10; IV; Q2DX3	Microtubule damage	17	0
		Docetaxel + Bevacizumab	10; IV; Q2DX3 10; IP; Q3DX10	Microtubule damage VEGF inhibitor	0	0
		Docetaxel + Herceptin	10; IV; Q2DX3 20; IP; Q7DX2	Microtubule damage Her2 inhibitor	13	0
		Docetaxel + Herceptin + Bevacizumab	10; IV; Q2DX3 20; IP; Q7DX2 10; IP; Q3DX10	Microtubule damage Her2 inhibitor VEGF inhibitor	0	0
		Docetaxel + Sorafenib	10; IV; Q2DX3 100; PO; QDX21	Microtubule damage Multi kinase inhibitor	20	0
		Doxorubicin + Cisplatin	1; IP; QDX5 150; IP; QDX1	Topoisomerase II inhibitor DNA damage	10	0
		Doxorubicin + Cyclophosphamide Bevacizumab	1; IP; QDX5 150; IP; QDX1 10; IP; Q3DX10	Topoisomerase II inhibitor DNA damage VEGF inhibitor	0	0
		Dasatinib	25; PO; QDX5X2	src kinase inhibitor	31	0
		Dasatinib + Bevacizumab	25; PO; QDX5X2 10; IP; Q3DX10	src kinase inhibitor VEGF inhibitor	20	0
		Imatinib	100; PO; QDX7	bcr-abl and c-kit inhibitor	0	0
		Imatinib + Bevacizumab	100; PO; QDX7 10; IP; Q3DX10	bcr-abl and c-kit inhibitor VEGF inhibitor	8	0
		Carboplatin + Bevacizumab	20; IP; QDX5 10; IP; Q3DX10	DNA damage VEGF inhibitor	0	0
		Carboplatin + Paclitaxel	50; IP; QDX1 6; IP; QDX5	DNA damage Microtubule damage	70	0
JH082	PDAC	Gemcitabine	100; IP; Q3Dx4	DNA replication	54	0
		Mitomycin C	5;IV;QDX1	DNA damage	5	0
		Erlotinib	100; PO; QDx10D	EGFR inhibitor.	45	0
		Rapamycin	40;PO; BIDX28D	mTOR inhibitor.	34	0
		PHA-848125	40; PO; BID x 28D	cdk inhibitor.	16	0
JH102	PDAC	Mitomycin C	5;IV;QDX1	DNA damage	97	100
		Erlotinib	100; PO; QDx10D	EGFR inhibitor	47	0
		Rapamycin	40;PO; BIDX28D	mTOR inhibitor	43	0
		Gemcitabine	100; IP; Q3Dx4	DNA replication	81	50
JH161	PDAC	Gemcitabine	100; IP; Q3Dx4	DNA replication	80	14
CBI-0602	MCS	Bortezomib + Bevacizumab	1; IV; Q3DX6 10; IP; Q3DX10	Protease inhibitor VEGF inhibitor	67	0
		Gemcitabine + Docetaxel + Bevacizumab	100; IP; Q3DX4 10; IV; Q7DX3 10; IP' Q3DX10	DNA replication Microtubule damage VEGF inhibitor	65	0

Sorafenib	60; PO; QDx10	Multi kinase inhibitor	38	0
Sorafenib+ Bevacizumab	60; PO; QDX10 10; IP; Q3DX10	Multi kinase inhibitor VEGF inhibitor	75	0
Doxorubicin + Cyclophosphamide	1; IV; QDX5 150; IP; QDX1	DNA damage DNA damage	65	0
Sorafenib + Bevacizumab	60; PO; QDX10 10; IP; Q3DX10	Multi kinase inhibitor VEGF inhibitor	69	0
Sunitinib + Bevacizumab	40; PO; QDX21 10; IP; Q3DX10	Multi kinase inhibitor VEGF inhibitor	67	0
Rapamycin + Bevacizumab	8; PO; QDX14 10; IP; Q3DX10	mTOR inhibitor VEGF inhibitor	0	0
Imatinib + Bevacizumab	100; PO; QDX7 10; IP; Q3DX10	bcr-abl and c kit inhibitor VEGF inhibitor	61	0
Irinotecan + Bevacizumab	100; IP Q7DX3 10; IP; Q3DX10	Topoisomerase I inhibitor VEGF inhibitor	70	0
Doxorubicin + Bevacizumab	2;IV; QDX5 10; IP; Q3DX10	Topoisomerase II inhibitor VEGF inhibitor	69	0
Perifosine	30; PO; QDX28	Akt inhibitor	67	0
Perifosine + Bevacizumab	30; PO; QDX28 10; IP; Q3DX10	Akt inhibitor VEGF inhibitor	84	33
Temozolamide	70;IP;QDX5X2	DNA damage	19	0
Temozolamide + Sorafenib	70;IP;QDX5X2 60; PO; QDx10	DNA damage Multi kinase inhibitor	11	0
Ifosfamine + Cisplatin	120; IP; QDX3 3; IP; QDX5	DNA Damage DNA Damage	66	0
Talabostat	0.8; PO; BIDX28	Dipeptidyl Peptidase Inhibitor	0	0
SLX-2119	100; PO; QDX21	RHO Kinase Inhibitor	16	0
SLX-3060	100; PO; QDX21	RHO Kinase Inhibitor	0	0
BP244	12;SC;CI	HIF-1 alpha	91	0
Ifosfamine + Bevacizumab	120; IP; QDX3 10; IP; Q3DX19	DNA damage VEGF inhibitor	86	0
Bortezomib + Sorafenib + Docetaxel	1; IV; Q3DX6 60; PO; QDX10 6.3; IV; Q2DX3	Proteasome inhibitor Multi kinase inhibitor Microtubule damage	72	0
Irinotecan + Docetaxel + Bevacizumab	10; IP; Q2DX9 10; IV; Q7DX3 10; IP; Q3DX10	Topoisomerase 1 inhibitor Microtubule damage VEGF inhibitor	95	0
Irinotecan + Docetaxel + Bevacizumab + Sorafenib	10; IP; Q7DX3 10; IV; Q7DX3 10; IP; Q3DX10 60; PO; QDX10	Topoisomerase 1 inhibitor Microtubule damage VEGF Inhibitor Multi kinase inhibitor	88	0
Bortezomib + Sorafenib + Docetaxel + Bevacizumab	1; IV; Q3DX6 60; PO; QDX10 6.3; IV; Q2DX3 10; IP; Q3DX10	Proteasome Inhibitor Multi kinase inhibitor Microtubule damage VEGF Inhibitor	86	0
Ifosfamide +	120; IP; QDX3	DNA damage		

		Bevacizumab+ Docetaxel	10; IP; Q3DX19 12.5; IV; Q7DX3	VEGF inhibitor Microtubule damage	86	0
CBI-0810	Breast	Cetuximab	20; IP; Q3DX8	EGFR inhibitor	0	0
		Temsirolimus	20/10; IV; Q3DX4	mTOR inhibitor	52	0
		Liposomal Doxorubicin	5; IV; Q7DX3	Topoisomerase II inhibitor	89	60
		Dasatinib	25; PO; qdx5x2	Src kinase inhibitor	39	0
		Cisplatin + Irinotecan	2.5/2; IP; Q7DX1/2 50/25; IP; Q7DX31/2	DNA damage Topoisomerase 1 inhibitor	100	100
		Trabectedin	0.15; IV; Q7DX3	DNA damage	100	100